Anxiolytic action of group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala

Pharmacological Reports

Volumn 57, Issue 6, 2005, Pages 734-743

  Wierońska, Joanna M ^a   Szewczyk, Bernadeta ^a   Pałucha, Agnieszka ^a   Brański, Piotr ^a   Zieba, Barbara ^a   Śmiałowska, Maria ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Anxiety; Immunohistochemistry; Metabotropic glutamate receptors; Neuropeptide Y

Indexed keywords

1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; CARBOXYCYCLOPROPYLGLYCINE; MESSENGER RNA; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MAZE TEST; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY; TRANQUILIZING ACTIVITY;

EID: 33645666210     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Britton KT, Southerland S, van Uden E, Kirby D, Rivier J, Koob G: Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology, 1997, 132, 6-13.
2. Capurro D, Huidobro-Toro JP: The involvement of neuropeptide Y Y1 receptors in the blood pressure baroreflex: studies with BIBP 3226 and BIBO 3304. Eur J Pharmacol, 1999, 376, 251-255.
3. Chojnacka-Wojcik E, Tatarczyńska E, Pile A: The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur J Pharmacol, 1997, 319, 153-156.
4. Corti C, Aldegheri L, Somogyi P, Ferraguti F: Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience, 2002, 110, 403-420.
5. Davis M: The role of the amygdala in fear and anxiety. Annu Rev Neurosci, 1992, 15, 353-375.
6. Davis M, Rainnie D, Cassell M: Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci, 1994, 17, 208-214.
7. Dumont Y, Cadieux A, Doods H, Fournier A, Quirion R: Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). Can J Physiol Pharmacol, 2000, 78, 116-125.
8. 1A compounds by GABA-benzodiazepine agents in rats. Pharmacol Biochem Behav, 1998, 60, 27-32.
9. Ferris P, Seward E, Dawson GR: Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol, 2001, 15, 76-82.
10. Fukui K, Kawashima Y, Iizumi H, Utsumi H, Nakajima T: Immunohistochemical alterations in neuropeptide Y-positive nerve elements in rat cerebral cortex following acute phencyclidine treatment. Neuroreport, 1995, 6, 626-628.
11. Fukui K, Kawashima Y, Iizumi H, Utsumi H, Nakajima T: The effects of acute phencyclidine treatment on neuropeptide Y (NPY) neuronal system in the rat arcuate nucleus studied by immunocytochemistry and in situ hybridization. J Neural Transm, 1996, 103, 385-390.
12. Gustafson EL, Card JP, Moore RY: Neuropeptide Y localization in the rat amygdaloid complex. J Comp Neurol, 1986, 251, 349-362.
13. Heilig M, McLeod S, Koob GK, Britton KT: Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept, 1992, 41, 61-69.
14. Heilig M, Soderpalm B, Engel JA, Widerlov E: Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl), 1989, 98, 524-529.
15. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ: Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther, 1998, 284, 651-660.
16. Kerkerian L, Bosler O, Pelletier G, Nieoullon A: Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci Lett, 1986, 66, 106-112.
17. Kerkerian L, Salin P, Nieoullon A: Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons. Neuroscience, 1988, 26, 809-817.
18. Krysiak R, Obuchowicz E, Herman ZS: Diazepam and buspirone alter neuropeptide Y-like immunoreactivity in rat brain. Neuropeptides, 1999, 33, 542-549.
19. Krysiak R, Obuchowicz E, Herman ZS: Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis. Eur J Endocrinol, 1999, 140, 130-136.
20. Lasoń W, Przewłocka B, Przewłocki R: The effects of excitatory amino acids on proenkephalin and prodynorphin mRNA levels in the hippocampal dentate gyrus of the rat; an in situ hybridisation study. Mol Brain Res, 1992, 12, 243-247.
21. Martin LJ, Blackstone CD, Huganir RL, Price DL: Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron, 1992, 9, 259-270.
22. Masugi M, Yokoi M, Shigemoto R, Muguruma K, Watanabe Y, Sansig G, van der Putten H, Nakanishi S: Metabotropic glutamate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion. J Neurosci, 1999, 19, 955-963.
23. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T et al.: Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo [3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem, 1997, 40, 528-537.
24. Morris BJ: Neuronal localisation of neuropeptide Y gene expression in rat brain. J Comp Neurol, 1989, 290, 358-368.
25. Paxinos G, Watson C: The rat brain in stereotaxic coordinates, 2nd edn. Academic Press Inc., San Diego, California, 1986, 92-101.
26. Pałucha A, Tatarczyńska E, Brański P, Szewczyk B, Wierońska JM, Klak K, Chojnacka-Wójcik E et al.: Group III mGlu. receptor agonists produce anxiolytic-and antidepressant-like effects after central administration in rats. Neuropharmacology, 2004, 46, 151-159.
27. Pellow S, Chopin P, File SE, Briley M: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods, 1985, 14, 149-167.
28. Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ: The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience, 1996, 71, 949-976.
29. Pile A, Chojnacka-Wojcik E, Tatarczyńska E, Borycz J, Kroczka B: Stimulation of group II metabotropic glutamate receptors or inhibition of group I ones exerts anxiolytic-like effects in rats. Amino Acids, 2000, 19, 81-86.
30. Przegaliński E, Tatarczyńska E, Chojnacka-Wojcik E: The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology, 2000, 39, 1858-1864.
31. Przewłocka B, Lasoń W, Przewłocki W: Time-dependent changes in the activity of opioid systems in the spinal cord of monoarthritic rats - a release and in situ hybridization study. Neuroscience, 1992, 46, 209-216.
32. Sajdyk TJ, Vandergriff MG, Gehlert DR: Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol, 1999, 368, 143-147.
33. Salin P, Nicoullon A, Kerkerian-Le Goff L: Reversal of the adaptive response of neuropeptide Y neurons in the rat striatum to nigrostriatal dopamine deafferentation by the N-methyl-D-aspartate antagonist dizocilpine maleate. Neuroscience, 1994, 61 93-105.
34. Scatton B: The NMDA receptor complex. Fundam Clin Pharmacol, 1993, 7, 389-400.
35. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N: Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett, 1993, 163, 53-57.
36. Śmiałowska M, Bajkowska M: Activation of metabotropic glutamate receptors increases neuropeptide Y expression in the rat hippocampus. Immunohistochemical studies. Pol J Pharmacol, 1997, 49, 357-362.
37. Śmiałowska M, Bajkowska M: Reserpine induces increase in neuropeptide Y immunoreactivity in rat amygdala neurons. Pol J Pharmacol, 1998, 50, 443-447.
38. Śmiałowska M, Bajkowska M, Przewlocka B, Maj M, Turchan J, Przewlocki R: Effect of 6-hydroxydopamine on neuropeptide Y and corticotropin- releasing factor expression in rat amygdala. Neuroscience, 1999, 94, 1125-1132.
39. Śmiałowska M, Legutko B: Influence of imipramine on neuropeptide Y immunoreactivity in the rat brain. Neuroscience, 1991, 41, 767-771.
40. Śmiałowska M, Szewczyk B, Branski P, Wierońska JM, Pałucha A, Bajkowska M, Pilc A: Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology, 2002, 42, 1016-1023.
41. Śmiałowska M, Wieronska JM, Branski P, Obuchowicz E, Pilc A: MPEP, mGlu5 receptor antagonist, regulates NPY mRNA expression in hippocampal and amygdalar neurons. Pol J Pharmacol, 2004, 56, 709-718.
42. Śmiałowska M, Wierońska JM, Wedzony K: A search for colocalization of mGluIa receptors with CRF or NPY in the rat brain amygdala. Folia Histochem Cytobiol, 2002, 40, 153-154.
43. Soderpalm A, Blomqvist O, Soderpalm B: The yohimbine-induced anticonflict effect in the rat, Part I. Involvement of noradrenergic, serotonergic and endozepinergic mechanisms. J Neural Transm Gen Sect, 1995, 100, 175-189.
44. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, Gentsch C: Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther, 2000, 295, 1267-1275.
45. Tatarczyńska E, Klodzinska A, Kroczka B, Chojnacka-Wojcik E, Pilc A: The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl), 2001, 158, 94-99.
46. Vogel JR, Beer B, Clody DE: A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology, 1971, 21, 1-7.
47. Wieronska JM, Brański P, Pałucha A, Śmiałowska M: The effect of competitive and non-competitive NMDA receptor antagonists, ACPC and MK-801 on NPY and CRF-like immunoreactivity in the rat brain amygdala. Neuropeptides, 2001, 35, 219-226.
48. Wierońska JM, Smialowska M, Branski P, Gasparini F, Klodzinska A, Szewczyk B, Palucha A et al.: In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling. Neuropsychopharmacology, 2004, 29, 514-521.